Merck Shares Reach $121.57 on Keytruda Strength and AI R&D Tie-Up
Merck & Co reported robust Keytruda sales drove share gains and contributed to an upward adjustment of 2026 earnings guidance; its shares closed at $121.57, valuing the company at about $303.66 billion. Merck also formed an AI-enabled drug discovery and precision medicine R&D collaboration with Mayo Clinic.
1. Strong Keytruda Performance and Guidance Increase
Merck recorded robust sales of its oncology and immunology drug Keytruda during Q4, leading management to raise 2026 earnings guidance. Positive clinical trial data on new indications reinforced investor confidence in the company’s growth trajectory.
2. Share Movement and Fund Inclusion
Merck’s stock delivered a one-month return of 9.41%, closing at $121.57 per share and valuing the firm at approximately $303.66 billion. Shares have traded between $73.31 and $123.33 over the past 52 weeks, and the company was highlighted as a top holding in the Impax US Sustainable Economy Fund.
3. AI-Enabled R&D Collaboration with Mayo Clinic
Merck entered a strategic partnership with Mayo Clinic to apply artificial intelligence in drug discovery and precision medicine. The collaboration leverages Merck’s R&D expertise and Mayo Clinic’s clinical data network to accelerate target identification and develop personalized therapies.